Animal Health Push Resilient Biotics is actively expanding into production animals with a strategic co-development with Novus International to create immune health feed solutions for swine. This creates business development opportunities with feed producers, veterinary distributors, and livestock integrators to license or co-develop microbiome-derived feed additives that support respiratory health and reduce disease risk. The microbial actives show immune activation and pathogen inhibition in respiratory tissues, offering a natural alternative to antibiotics across animal supply chains.

Strategic Collaborations Recent partnerships with CosmosID and Novus signal openness to collaboration with data analytics, microbiome discovery, and animal feed developers. Target large life science platforms, CROs, and nutraceuticals for joint R&D and commercialization. Pursue staged collaborations to expand the pipeline and accelerate go-to-market timelines in both human and animal health.

Product Development The broad pipeline addressing viral and bacterial infections across species positions Resilient Biotics to tailor products for respiratory health in humans and animals. Opportunities include licensing or co-development of strains for clinical programs, veterinary medicines, or feed additives, supported by in vivo efficacy data. Develop monetization strategies through partnerships with pharmaceutical companies and animal health firms.

Market Opportunity Growing demand for antibiotic-sparing microbiome therapies in human healthcare and livestock farming presents a multi-market opportunity. Target segments include swine production, companion animal health, and human respiratory therapeutics, aligned with current partnerships and the company’s discovery capabilities.

Capabilities Advantage The company’s proprietary discovery platform combines high-resolution genomics, in-house machine learning, and targeted in vitro assays to identify immune-activating and pathogen-inhibiting strains. These capabilities can be leveraged to offer bespoke R&D services or CRO partnerships, attracting alliances with larger biotech firms seeking novel microbiome assets.